The skeleton is the third most common site for cancer cell metastasis after the lungs and liver. Almost all malignant tumors can metastasize to the bones, accompanied by various serious complications. Among the comprehensive treatment methods for tumors, surgical resection remains the most effective measure, but it may leave residual tumor cells in the surgery area, potentially leading to postoperative recurrence. In such cases, cryoablation for bone cancer has made significant progress, promising long-term disease control and symptom relief.
Cryoablation for bone cancer utilizes the tip of an ultra-cold surgical instrument. When room temperature, high-pressure argon gas(coolant) is delivered, the tip rapidly freezes the diseased tissue to below -100℃ within seconds (coolant). When room temperature helium gas(heat medium) is delivered, the tip quickly heats the frozen diseased tissue, causing the target area cells to burst. Repeating the freeze-thaw process twice can rupture and destroy tumor cells within the target area, damage and thrombose microvascular endothelial cells, and reverse tumor immunosuppression.
Cryoablation technology uses a low-temperature freezing method. The cryoprobe directly applies extreme cold to the tumor tissue, causing the tumor cells to die rapidly at low temperatures. This treatment method does not require large incisions, minimally damaging the surrounding normal tissue. Patients recover quickly with less pain. Compared to traditional surgical resection, cryoablation is more minimally invasive and can significantly improve the quality of life for patients.
The long-term control effect of cryoablation for bone cancer is also very significant. By directly destroying tumor tissue and immune stimulation, cryoablation can effectively control tumor growth and spread. Multiple studies have shown that bone cancer patients treated with cryoablation have a lower recurrence rate and a significantly longer survival period. This long-term control effect provides patients with more treatment options and hope.
Oligometastatic Tumors: Cryosurgery ablation can treat multiple lesions in patients with a limited number of bone and soft tissue metastases, achieving good therapeutic effects. It can be an excellent choice.
Benign and Low-Grade Malignant Tumors: Experts recommend using cryoablation as the primary treatment for small benign bone tumors without bone destruction. Patients with benign invasive bone tumors can benefit from combining traditional surgery with cryoablation. For those unable to tolerate medication, cryoablation may be considered.
Metastatic Tumors: If patients with painful metastases do not have significant neurological compression or localized bone destruction, they can undergo cryoablation for effective pain relief.
In general, considerable research has demonstrated the efficacy and safety of cryoablation for treating bone metastases. It can promptly and continuously relieve pain, achieve local tumor control, and has a low incidence of major complications. With continuous advancements in medical technology, cryoablation will become more precise and safer, leading to better outcomes in bone cancer treatment.
HYGEA, a pioneering leader in the field of medical technology. We are dedicated to advancing healthcare through innovative solutions and cutting-edge cryosurgery tools. Our flagship product, the AI Epic™ Cryosurgical System, represents the pinnacle of precision and efficiency in cryoablation procedures. Designed for minimally invasive and non-invasive tumor removal, the AI Epic™ system leverages advanced AI technology to deliver unparalleled accuracy and patient outcomes. Discover how HYGEA is transforming the landscape of cryosurgery with the AI Epic™ Cryosurgical System.
Hygea Medical Technology Co., Ltd.
Hygea Medical Technology Co., Ltd.
EN 
